Chordin is a bone morphogenetic protein (BMP) inhibitor that has been identified as a factor dorsalizing the Xenopus embryo. A novel secreted protein, CHL (for chordin-like), with significant homology to chordin, was isolated from mouse bone marrow stromal cells. Injection of CHL RNA into Xenopus embryos induced a secondary axis. Recombinant CHL protein inhibited the BMP4-dependent differentiation of embryonic stem cells in vitro and interacted directly with BMPs, similar to chordin. However, CHL also weakly bound to TGF␤s. In situ hybridization revealed that the mouse CHL gene, located on the X chromosome, was expressed predominantly in mesenchyme-derived cell types: (1) the dermatome and limb bud mesenchyme and, later, the subdermal mesenchyme and the chondrocytes of the developing skeleton during embryogenesis and (2) a layer of fibroblasts/connective tissue cells in the gastrointestinal tract, the thick straight segments of kidney tubules, and the marrow stromal cells in adults. An exception was expression in the neural cells of the olfactory bulb and cerebellum. Interestingly, the spatiotemporal expression patterns of CHL were distinct from those of chordin in many areas examined. Thus, CHL may serve as an important BMP regulator for differentiating mesenchymal cells, especially during skeletogenesis, and for developing specific neurons.
INTRODUCTION
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor (TGF)␤ superfamily and were originally identified as factors promoting the ectopic formation of cartilage and bone (reviewed in Wang, 1993) . BMPs are also known to play an essential role during the early embryogenesis of Drosophila, Xenopus, zebrafish, and mammals (reviewed in Harland and Gerhart, 1997) . Moreover, BMPs are involved in cell-type specification during the organogenesis phase of embryogenesis (reviewed in Hogan, 1996) . In any case, BMPs are pleiotropic factors, and the precise concentration of active BMP seems to be important for rendering a particular biological effect. In fact, an activity gradient of BMP is formed during embryogenesis in Drosophila as well as in Xenopus, which leads to the generation of different cell types, depending on the location (i.e., the local BMP concentration) (reviewed in Dale and Wardle, 1999; Podos and Ferguson, 1999) .
The active BMP concentration is controlled in part through the influence of BMP inhibitors. Several BMP binding proteins have been described: short gastrulation/ chordin (Francois et al., 1994; Pappano et al., 1998; Sasai et al., 1994; Schulte-Merker et al., 1997) , noggin (Smith and Harland, 1992; Zimmerman et al., 1996) , and cerberus (Belo et al., 1997; Biben et al., 1998; Bouwmeester et al., 1996) . Among them, chordin and noggin are known to inhibit the activity of bound BMP by preventing it from binding to its receptor (Piccolo et al., 1996; Zimmerman et al., 1996) . Chordin is a secreted protein produced from the Spemann's organizer of the Xenopus embryo and functions as a dorsalization factor by antagonizing the ventralizing factor, BMP4. The binding affinity of chordin to BMP4 is specific and tight (Piccolo et al., 1996) , and proteolysis seems to be required to effectuate the release of bound BMP4. The chordin polypeptide contains four cysteine-rich units designated procollagen repeats (CRs), which are also found in a variety of extracellular matrix proteins, such as collagen and thrombospondin. The first and third CRs (CR1 and CR3) of chordin are responsible for BMP binding (Larrain et al., 2000) . Proteolytic degradation of chordin is accomplished by a metalloprotease, Tolloid or BMP1, that liberates both CR1 and CR4 (Piccolo et al., 1997; Scott et al., 1999) .
It is conceivable that, if expressed at the same time and location, any of the BMP binding inhibitors would functionally compensate for each other. This is the case for chordin and noggin in the mouse Brunet et al., 1998; McMahon et al., 1998) . Mouse chordin mRNA is first detected in the anterior primitive streak and then in the node and axial mesoderm. At the midgastrula stage, chordin expression overlaps with that of noggin. Mutational analyses have shown that the early embryonic functions of chordin and noggin are individually dispensable for embryonic development. However, chordin is essential for inner and outer ear development as well as for pharyngeal and cardiovascular organization . Similarly, noggin null-mutant mice display multiple developmental defects occurring at late stages of embryogenesis, including limb and digit defects caused by chondrocyte hyperplasia (Brunet et al., 1998; McMahon et al., 1998) . In contrast, double mutants show early embryonic phenotypes . Thus, these BMP inhibitors seem to share biological roles during early embryogenesis, whereas the roles of the individual inhibitors become specialized in later stages of development, so that some functions of chordin are no longer compensated by noggin or other BMP inhibitors.
Functional redundancy often occurs in members of the same gene family. Cerberus is known to form a large gene family: cerberus/Cer1 Bouwmeester et al., 1996; Shawlot et al., 1998) , DAN (Ozaki et al., 1996; Stanley et al., 1998) , Gremlin/Drm (Hsu et al., 1998; Topol et al., 1997) , and Dte (Pearce et al., 1999) . It has recently been shown that noggin also forms a family in zebrafish (Fuerthauer et al., 1999) . However, thus far, no functional redundancy has been demonstrated within these families. On the contrary, differences in the spatial as well as temporal order of expression during embryogenesis have been demonstrated, suggesting a different biological role for each member of the family. In the case of zebrafish noggin, noggin1 is expressed earliest and is active in dorsalizing the embryo, while noggin3 is the latest expressing member and probably functions during organogenesis. Recently, a large secreted Xenopus protein containing 27 CRs, which shows chordin-like dorsalizing activity in Xenopus embryos, was identified (Matsui et al., 2000) . Here, we provide evidence that a novel chordin family member, CHL (for chordinlike), is a BMP inhibitor, and the gene is localized on the X chromosome and is expressed preferentially in mesenchymal cell lineages with spatial and temporal patterns distinct from those of chordin. Potential roles of CHL during several organogenic processes are also discussed.
MATERIALS AND METHODS

Cells and reagents.
Polymerase chain reaction (PCR) and cDNA synthesis were performed with Advantage Taq (Clontech, Palo Alto, CA) and the Superscript cDNA library kit (Gibco/BRL, Gaithersburg, MD), respectively, according to the manufacturer's recommendations. Other enzymes were purchased from New England BioLabs (Beverly, MA) or Boehringer Mannheim (Indianapolis, IN). The human erythropoietin (EPO) cDNA was kindly provided by S. Wooden (Amgen).
The E14 ES cells and the OP9 stromal cell line were obtained and cultured as described (Nakayama et al., 1998 (Nakayama et al., , 2000 . The human kidney epithelial cell lines, 293 and 293T, were maintained in Dulbecco's modified essential medium (DMEM, Gibco/BRL) supplemented with 10% fetal calf serum (FCS, Hyclone, Logan, UT) at 37°C under 5% CO 2 . All tissue culture flasks and plates were from Falcon (Franklin Lakes, NJ).
Recombinant human BMP4, BMP5, BMP6, activin A, TGF␤2, and BMPR1BFc were purchased from R&D Systems (Minneapolis, MN). The corresponding antibodies used for Western blot detection were the anti-human BMP4 mouse monoclonal antibody from Chemicon (Temecula, CA), the anti-human BMP5 goat polyclonal antibody from R&D, the anti-human BMP6 mouse monoclonal antibody from Chemicon, the anti-human activin A goat polyclonal antibody from R&D, and the anti-human TGF␤2 goat polyclonal antibody from R&D. A human IgG Fc control was obtained from Zymed (South San Francisco, CA). The monoclonal antibody for mouse CD34 (clone RAM34) conjugated with fluorescein isothiocyanate (FITC) was purchased from Pharmingen (San Diego, CA). Phycoerythrin (PE)-conjugated monoclonal antibodies for mouse CD31 (clone MEC13.3) and CD45 (clone 30F11) were also purchased from Pharmingen.
Isolation of mouse CHL cDNAs. Normalized cDNAs were prepared with poly(A) ϩ RNA isolated from OP9 cells according to the PCR-based normalization procedure (Takahashi and Ko, 1994) . Small fragments (500 -1000 bp) were used to construct a library for yeast-based signal sequence trap screening (Jacobs et al., 1997; Klein et al., 1996) . An unnormalized cDNA library was also constructed in pSPORT1 (Gibco/BRL). From one pool of the normalized OP9 library (3 ϫ 10 5 independent clones) screened, a cDNA fragment encoding a putative NH 2 -terminal amino acid sequence of a protein with significant homology to chicken chordin, which was designated CHL, was identified by a Blast search (Genomics Computer Group, Madison, WI) . Using this partial cDNA as a probe, the corresponding full-length cDNA clone, mCHL(s2), was isolated from the unnormalized cDNA library (pSPORTmCHL(s2)). Furthermore, another cDNA clone designated mCHL(l3) that potentially encoded a different form of CHL was isolated from the mouse E15.5 embryo library (GIBCO/ BRL). For stable expression, the full-length mCHL(s2) cDNA was cloned into pcDNA3.1 (Invitrogen, Carlsbad, CA) to obtain pcDNAmCHL(s2), and for transient expression, the same cDNA was cloned into an SR␣-based expression plasmid (Takebe et al., 1988) to yield pSR␣mCHL(s2). As a negative control, pSR␣hEPO carrying the human EPO cDNA in place of mCHL(s2) was also constructed.
Isolation of human CHL cDNAs. Total RNA was isolated from rat prostate, poly(A) ϩ RNA was purified, and normalized cDNA inserts were prepared as described above. A longer range of cDNAs (Ͼ 1000 bp) was used to construct a cDNA library for expression sequence tag (EST) analysis (Adams et al., 1991) . A sequence containing a partial ORF almost identical to that of the mCHL cDNA was identified and was used as a probe to isolate full-length human CHL cDNAs. Screening of human prostate and fetal brain cDNA libraries (Stratagene, La Jolla, CA) resulted in four different forms of human CHL cDNAs, designated hCHL(l1) to hCHL(l4). All were cloned into pcDNA3.1 to yield pcDNAhCHL(l1), pcDNAhCHL(l2), pcDNAhCHL(l3), and pcDNAhCHL(l4). To construct hCHL(s1) and hCHL(s2), the exon-9 -intron 9 boundary region was first amplified by PCR with the sense primer 5Ј-AGCAAGAGTGTAAGAAAATCCAC-3Ј and the antisense primer 5Ј-AGAATCTCAGTCAACCAAAAGC-3Ј using human genomic DNA as the template. The amplified fragment was then cloned into pCR II-TOPO (Invitrogen), excised with ClaI and NotI, and transferred
FIG. 1.
Schematic representation of CHL and chordin gene products. (A) Schematic representation of mouse CHL (CHL(s) and CHL(l)) and chordin (CHD) gene products. CR and SP stand for the procollagen repeat and the signal peptide, respectively. The cluster of putative BMP1/Tolloid cleavage sites is indicated with an asterisk. The CR1 and CR3 in mouse CHL are homologous with CR3 of mouse chordin, indicated with black boxes. The two sites, at which amino acid sequence variations were found in the CHL ORF, are shown by dE and d5 in parentheses. The dE indicates E 95/96 missing in the l2, l4, and s2 forms of CHL, and d5 indicates the GKKAK sequence deleted in the l3 and l4 forms. (B) Amino acid sequences of the human CHL(l1) and CHL(l4) and mouse CHL(l3) and CHL(s2) protein precursors. The three CRs are indicated as boxes. The E 23 indicated by the vertical arrow was determined as the NH 2 -terminal amino acid of the mature mCHL(s2)-FLAG protein. The amino acid with an asterisk corresponds to the potential BMP1/Tolloid cleavage site. The E 95/96 missing in hCHL(l4) as well as in mCHL(s2) and the GKKAK stretch deleted in hCHL(l4) are indicated with black backgrounds. (C) Schematic representation of the partial intron-exon structure of the hCHL gene and transcripts. The top is the partial genomic organization based on AL049176. The vertical bars are exons, which correspond to thick horizontal bars/arrows in the two potential CHL transcripts shown underneath (CHL(s) and CHL(l)). The thin lines of the transcripts indicate splicing. The E 95/96 deletion mutation, indicated as dE, is created by an alternative splicing acceptor at the junction of intron 4 (Int4) and exon 5 (Ex5). The GKKAK deletion mutation, indicated as d5, is generated at the junction between exon 9 (Ex9) and intron 9 (Int9). The gray vertical bar in intron 9 indicates the region corresponding to the 3Ј-UTR of the CHL(s) transcript.
to the ClaI-NotI sites of pcDNAhCHL(l1) and pcDNAhCHL(l2) to obtain pcDNAhCHL(s1) and pcDNAhCHL(s2), respectively.
Construction of the FLAG-tagged mouse CHL(s2) and chordin: mCHL(s2)-FLAG and mCHD-FLAG. The mCHL(s2) ORF was mutated to replace the stop codon with a BamHI site by PCR using the sense primer 5Ј-GCTAGCGGCCGCGCCACCATGGATGG-CATGAAATACATCATTTC-3Ј and the antisense primer 5Ј-GGTACCGGATCCACCAAAGGCAGGGCCTCCAGC-3Ј. The amplified DNA fragment was digested with NotI and BamHI and was then inserted into the NotI-BamHI sites of the pFLAG-CMV-5a expression vector (Sigma) to attach the FLAG sequence in frame with the mCHL(s2) sequence at its COOH-terminus (mCHL(s2)-FLAG). The resultant plasmid was designated pFLAGmCHL(s2).
Next, mouse chordin cDNA was isolated by reverse transcriptase (RT)-PCR from the mouse E7 embryo cDNAs (Clontech, Palo Alto, CA) using the sense primer 5Ј-GCTAGCGGCCGCGCC-ACCATGCCGAGCCTCCCGGCCCCG-3Ј and the antisense primer 5Ј-GGATCCGTCGACGGAGTGCTCCGCTTCTTTCTC-CAG-3Ј. The amplified PCR product was digested with NotI and SalI and was then inserted into the NotI-SalI sites of pFLAG-CMV5a, which resulted in a COOH-terminal FLAG fusion protein of the mouse chordin (mCHD-FLAG), to yield pFLAGmCHD.
Production and detection of the recombinant mouse CHL(s2) and chordin proteins. The FLAG-tagged proteins were detected by direct Western blot analysis with 10 g/ml of the anti-FLAG mouse monoclonal antibody M2 (Sigma), according to the manufacturer's recommendations. Rabbit polyclonal antibodies for mCHL and mouse chordin were raised with synthetic peptides based on the NH 2 -terminal amino acid sequences of their presumptive mature proteins: NH 2 -SKTEQVKHSDTYC-COOH for mCHL and NH 2 -ALPIRSEKEPLPVRGAAGC-COOH for chordin (Harlow and Lane, 1988) . The resulting antisera were either used directly or subjected to affinity purification with the corresponding peptides (Harlow and Lane, 1988) .
To establish cell lines stably expressing the mCHL(s2)-FLAG or mCHD-FLAG protein, 293 cells were transfected with linearized pFLAGmCHL(s2) or pFLAGmCHD mixed with linearized pKJ1 (Adra et al., 1987) , using the calcium phosphate method (Sambrook et al., 1989) . Stable transfectants were then selected in 570 g/ml G418 (Gibco/BRL). The expression levels of the corresponding FLAG-tagged protein, in both the serum-free conditioned media (DMEM, 48 h) and the cell lysates, were compared by Western blot analysis using the M2 antibody or the affinity-purified anti-NH 2 -terminal peptide antibody (diluted 1:500 to 1:1000) (Harlow and Lane, 1988) . Conditioned media were concentrated 10-fold by Centricon ultrafiltration (Millipore, Bedford, MA) before Western blotting. The proteins were visualized with peroxidase-conjugated anti-mouse or anti-rabbit IgG secondary antibody (Pierce, Rockford, IL) and the chemiluminescent ECL kit (Amersham/ Pharmacia, Piscataway, NJ).
Similarly, transient transfection-based expression was carried out with 293T cells using the SuperFect transfection reagent (Qiagen, Valencia, CA) according to the manufacturer's suggested protocol. Twenty-four hours later, the medium was changed to serum-free media, such as 293 SFM II (Gibco/BRL), DMEM, and DMEM with 50 g/ml iron-saturated human transferrin (Sigma) and 10 g/ml bovine insulin (Boehringer Mannheim), and the cells were cultured for another 48 h. Tenfold concentrated conditioned media were then analyzed by Western blotting.
Partial purification of the FLAG-tagged mouse CHL(s2) and chordin proteins. For midscale preparation, the stable clones were expanded in suspension using 293 SFM II in a 3-liter spinner flask, and 3-day conditioned media for mCHL(s2)-FLAG and 6-day conditioned media for mCHD-FLAG were collected. An expression level of approximately 0.1-0.2 g/ml was obtained. The FLAGtagged proteins were partially purified by a single step of affinity chromatography using the anti-FLAG M2 affinity gel (Sigma) according to the manufacturer's recommendations. The protein concentration of each preparation was determined by Western blot analysis with M2 and comparison with the FLAG bacterial alkaline phosphatase standard (Sigma).
Co-immunoprecipitation analysis. Immunoprecipitation was performed as described (Piccolo et al., 1996) . Briefly, for the high concentration conditions, 0.4 g mCHL(s2)-FLAG or 1.2 g mCHD-FLAG was mixed with 0.2 g of BMP, activin A, or TGF␤2 in 1 ml of binding buffer, and the solution was incubated for 1 h at 4°C. Then, either 1.5-4 g of affinity-purified anti-peptide antibody or 40 l of crude antisera was added, and the solution was incubated for another 1 h. Next, 20 l protein A or 30 l of protein A/G plus agarose beads (Santa Cruz) was added, and the mixture was incubated for another 3 h to overnight. For the low concentration conditions, 0.1 g of mCHL(s2)-FLAG or 0.3 g of mCHD-FLAG was mixed with 90 -100 ng of BMP or activin A, and the reaction was processed in the same way. To demonstrate the role of CHL in BMP4 binding to the BMP receptor (BMPR), 100 ng of BMP4 and various amounts of mCHL(s2)-FLAG were mixed in 1 ml of binding buffer, and then 1 g of BMPR1BFc or IgG Fc was added. The resulting BMPR complex was precipitated directly with 20 l of protein A beads. The isolated immunocomplexes were electrophoresed through SDS-polyacrylamide gels under reducing conditions and then were blotted onto nitrocellulose membranes. The filter was treated with 0.4 g/ml anti-BMP4, 0.1 g/ml anti-BMP5, 0.1 g/ml anti-BMP6, 0.4 g/ml anti-activin A, or 1 g/ml anti-TGF␤2 antibody for 2 h at room temperature, and the bound antibodies were visualized as described.
Ectopic axis formation in Xenopus embryo. To examine the mouse and human CHL protein activities, pcDNAmCHL(s2), pcDNAhCHL(l1), pcDNAhCHL(l2), pcDNAhCHL(s2), and pcDNAhCHL(s2) were linearized with NotI, and capped mRNAs were synthesized with T7 RNA polymerase using the mMESSAGE mMACHINE kit (Ambion, Austin TX) and were quantified as described (Nishinakamura et al., 1999) . For mCHL(s2)-FLAG, the EcoRI-ScaI fragment of pFLAGmCHL(s2) was cloned into the EcoRI-NotI sites of pBluescript RN3 (Lemaire et al., 1995) , linearized with SfiI, and transcribed with T3 RNA polymerase using the mMESSAGE mMACHINE kit. For mCHD-FLAG, the NotI-ScaI fragment of pFLAGmCHD was introduced into the NotI-SmaI sites of the pBluescript (SK ϩ ) vector (Stratagene), which was then linearized with ClaI and transcribed in the same way. As a negative control, elongation factor 1 (EF1) RNA was synthesized using the template included in the kits. Xenopus embryos were also prepared for injection as described (Nishinakamura et al., 1999) . Five nanoliters of each RNA was injected into two ventral blastomeres of a four-cell stage embryo. After the injection, the embryos were cultured in 10% Steinberg's solution for 48 h and were then scored for the ectopic axis.
In vitro differentiation of embryonic stem cells under serumfree conditions. Briefly, E14 embryonic stem (ES) cells were transferred to a gelatin-coated plate, adjusted for 2 days in serumfree medium, and then subjected to differentiation in serum-free methylcellulose medium in the presence of 0.6 ng/ml BMP4 as described (Nakayama et al., 2000) . Embryoid bodies were collected on day 7 and were dissociated with collagenase. The cells were stained with monoclonal antibodies for hematopoietic progenitor cell markers, such as CD31, CD34, and CD45, as described (Nakayama et al., 2000) . The stained samples were analyzed on a FACScan (Becton-Dickinson, San Jose, CA).
In situ hybridization and Northern blot analyses. Northern blotting was performed (Sambrook et al., 1989) with multiple mouse tissue Northern blots purchased from Clontech, using the 32 P-labeled NotI-BamHI fragment from pFLAGmCHL(s2) that contained the entire ORF of mCHL(s2) as a probe. The chordin transcript was detected on the same blots with the 32 P-labeled NotI-SalI fragment from pFLAGmCHD containing the intact ORF of mouse chordin. For detecting the mCHL(s)-specific transcripts, a probe (designated the intron 9 probe) was made by PCR with the p r i m e r s 5 Ј -C C T G C C T T T G G T T G A A T G A G -3 Ј a n d 5 Ј -GGAGATAGAGGTTAGATAGTAG-3Ј, which were derived from the nucleotide sequence of the 3Ј-untranslated region (UTR) of the mCHL(s2) cDNA.
In situ hybridization to embryonic and adult mouse tissue sections was carried out according to Wilcox (1993) . For the CHL probe, the ClaI-NotI region of pSPORTmCHL(s2) was removed to obtain pSPmCHL5Ј, which was then linearized with EcoRI. The antisense RNA was synthesized with SP6 RNA polymerase. For chordin, the 1.4-kb BamHI-BglII fragment of pFLAGmCHD was transferred into the BamHI site of the pBluescript (SK Ϫ ) vector (Stratagene), which was linearized with EcoRI. The antisense RNA was synthesized with T3 RNA polymerase. Shi et al. (1997) . The probe was a BAC clone, F1038, isolated from the mouse ES-129/SvJ II BAC chromosome DNA library (Genome Systems) by PCR using the sense primer 5Ј-TTACCACCAGTGAAC-AATAAGG -3Ј and the antisense primer 5Ј-CTTGAGACCAC-AGTATACATTCC-3Ј, which correspond to the second CR domain of mCHL(s2), and with the sense primer 5Ј-AGTG-CCCAGCTTTAGTCCAC-3Ј and the antisense primer 5Ј-GTT-CTGTTTTGCTTCCTTCTAG-3Ј, which cover the 5Ј-UTR and the signal peptide region. To determine the location of the mouse CHL gene on the X chromosome, the X centromere-specific P1 clone (No. 6856) was also used as a cohybridization probe (Shi et al., 1997) . A total of 80 metaphase cells were analyzed, and of the 72 that exhibited specific labeling,10 were used for cohybridization experiments.
RESULTS
Cloning of a cDNA Encoding a Novel Chordin-like Gene Product from the Mouse Bone Marrow Stromal Cell Line OP9
The OP9 stromal cell genomics resulted in a cDNA encoding a 333-amino-acid protein precursor consisting of a potential signal peptide followed by three CRs similar to the chordin CRs. The homology with the chordin CRs ranged from 40 to 53% by a Blast search, which was statistically significant compared with the CRs of other proteins, such as thrombospondin and collagen (data not shown). Therefore, the predicted protein was designated CHL for chordin-like (Fig. 1A) . During the course of the full-length mouse CHL (mCHL) cDNA cloning, a partial clone encoding a variant of mCHL was identified from an E15.5 mouse embryo cDNA library. This had an insertion of one glutamate residue at position 96 (E 96 ) and carried a longer COOHterminal sequence (Fig. 1B) . Assuming that both forms share the same 5Ј-end sequence, the predicted full-length ORF would consist of 448 amino acids, which is larger than the first form. Human CHL (hCHL) cDNAs were also isolated, and all of them resembled the longer form of mCHL. A sequence analysis indicated that there were small deletions at two sites within the coding region, which would make four different hCHL products (Fig.  1B) . The longest encoded a protein of 452 amino acids and was designated hCHL(l1). The suffix "l" in parentheses stands for the long form, and "1" stands for no deletion. At one site, one amino acid, E 95 , was missing, which gave rise to a 451-amino-acid protein (hCHL(l2)). At the other site, a 15-bp segment encoding G 319 -K-K-A-K 323 was missing, which resulted in a 447-amino-acid protein (hCHL(l3)). A double mutant was also obtained (hCHL(l4)). The suffix "2" means the deletion of E 95 (E 96 in mice), "3" stands for the deletion of the GKKAK stretch, and "4" corresponds to mutations at both sites. Therefore, the original mouse clone was renamed mCHL(s2), in which the suffix "s" in parentheses stands for the short form, and the second mouse clone was designated mCHL(l3). CHL(l) and CHL(s) represent the long forms and the short forms, respectively. The mouse chordin protein consists of four CRs and is approximately 2 to 2.8
The proteins in the peak eluate from anti-FLAG affinity column chromatography (12 g/ml mCHL(s2)-FLAG determined by Western) were separated by SDS-polyacrylamide gel electrophoresis under reducing conditions and were stained with Coomassie brilliant blue (Sambrook et al., 1989) . The arrow indicates the mCHL(s2)-FLAG protein band. This band was excised, and the NH 2 -terminal amino acid sequence of the extracted peptide was determined (the vertical arrow in Fig. 1B ) to confirm the identity of the band. (B) Western blot analysis of the purified mCHD-FLAG protein (lane 1) and mCHL(s2)-FLAG protein (lane 2). The purified FLAG-tag proteins were visualized with M2 (␣FLAG). The arrows indicate the intact mCHL(s2)-FLAG (top) as well as the COOH-terminal portion of the degradation product (lower duplex). (C) Stability of the mCHL(s2) protein. The stable 293 clone for mCHL(s2)-FLAG was plated at 1 ϫ 10 6 cells/well in a 6-well plate. Twenty-four hours later, the medium was changed to 2 ml each of 293 SFM II (lane 2), DMEM (lane 3), or DMEM with transferrin and insulin (lane 4), and the cultures were incubated further for 48 h. Transient transfection of 293T cells was also performed with pSR␣hEPO (lane 6) and pSR␣mCHL(s2) (lane 7), and 48-h conditioned media were made with DMEM. All of the culture supernatants were equally concentrated and 40 l of each was subjected to Western blot analysis with the anti-mCHL antibody (␣NH2-mCHL). Lanes 1 and 5 are the purified mCHL(s2)-FLAG proteins. The arrows indicate the intact size of the mCHL(s2) protein (top) as well as the NH 2 -terminal portion of the degradation product (bottom).
times larger than the mCHL proteins (945 amino acids), as illustrated in Fig. 1A . The CR1 and CR3 of mCHL were most similar to the CR3 of mouse chordin (indicated by black boxes).
The cloning frequency of the different forms of hCHL was not random. For instance, five of five clones isolated from the prostate cDNA library were either hCHL(l3) or hCHL(l4). However, the PCR-based cloning of hCHL from human brain, heart, and prostate cDNAs followed by DNA sequencing revealed that all forms were found in all three tissues (data not shown). Therefore, no tissue-specific expression of any form has been demonstrated. So far, no hCHL cDNA equivalent to mCHL(s2) has been identified, and no mouse equivalents of hCHL(l1), hCHL(l2), and hCHL(l4) have been cloned.
Both Mouse and Human CHL Genes Are Located on the X Chromosome
A partial sequence of the hCHL gene was found in GenBank (Accession No. AL049176). The sequence is derived from the q22.1-23 region of the human X chromosome, and it was found to contain a region from exon 3 to exon 12 of the hCHL gene. The mCHL gene was mapped by FISH using a BAC clone DNA with a chromosomal DNA segment containing CHL exons as a probe. The mCHL gene was located at a position 89% of the distance from the heterochromatic-euchromatic boundary to the telomere of the X chromosome, which corresponds to band XF3. Therefore, both the human and mouse CHL genes are located on the X chromosome.
The Multiple Forms of the CHL cDNAs Were Probably Created by Alternative Splicing and Alternative Transcriptional Termination
It was evident from the AL049176 genomic DNA sequence that hCHL(l2) could be formed by the use of an alternative splice acceptor for intron 4 and that hCHL(l3) was likely to be generated by the use of an alternative splice donor for intron 9 (Fig. 1C) . The mCHL(s2) protein ended 10 amino acids (GALAGGPAFG) after the GKKAK sequence (Fig. 1B) . It was found from the human genomic sequence that an almost identical amino acid stretch, GALVGG-PAFG, could be added after GKKAK if no splicing of intron 9 occurred. This would also result in an almost identical size as the mCHL(s2) protein (333 and 332 amino acids for hCHL(s1) and for hCHL(s2), respectively). The 3Ј-UTR of the mCHL(s2) cDNA was homologous to intron 9 of the hCHL gene, but not to the hCHL(l) 3Ј-UTR in exon 12 (data not shown). These observations suggest that the CHL(s) cDNAs were probably derived from the CHL transcripts that prematurely terminated within intron 9 or from the splice variants retaining intron 9. On the other hand, the 3Ј-UTR of the mCHL(l3) cDNA was homologous to the hCHL(l) 3Ј-UTR, suggesting that the mCHL(l3) transcript stops at a similar site as the hCHL(l) transcripts. Thus, the CHL variants were probably generated by alternative splicing and/or alternative transcriptional termination. 1-1 g) , and then BMPR1BFc was added. The resulting BMPR complex was precipitated, and the bound BMP4 was visualized. (Bottom panel) Binding specificity of BMP4 to the BMPR1B extracellular domain was confirmed. Note that BMP4 was not coprecipitated with human IgG Fc. For the standard (S), 20 ng of BMP4 was loaded directly.
CHL Induced a Secondary Axis in the Xenopus Embryo: Evidence for in Vivo Interaction with BMP
Chordin is known to dorsalize the gastrulating Xenopus embryo by inhibiting the activity of BMP4. Therefore, the effects of the CHLs on Xenopus embryo development were examined ( Fig. 2 and Table 1 ). When 10 -30 pg RNA was injected per blastomere, the axis duplication rates for mCHL(s2) and for mCHL(s2)-FLAG ranged from 79 to 87%, whereas the rate for the uninjected control embryos and the EF1 RNA-injected embryos was 0% (Table 1) . As a positive control, experiments were also performed with the mCHD-FLAG RNA, and an axis duplication rate similar to that of mCHL(s2) was obtained (Table 1) . Thus, mCHL(s2), with or without a FLAG tag at the COOH terminus, was active in antagonizing the endogenous ventralizing factor (presumably BMP4). The hCHL constructs, including long forms (l1 and l2) and short forms (s1 and s2), displayed essentially the same effect as mCHL(s2), although the maximum tolerable amount of RNA (1 ng) was required. This result indicates that all forms of CHL tested were active in antagonizing the Xenopus ventralizing factor and suggests that the mouse CHL seemed to be more active in Xenopus embryos than the human CHLs.
The mCHL(s2) Protein Is Potentially Cleaved between CR2 and CR3
Further protein analyses were carried out with mCHL(s2). As shown in Figs. 3A and 3B, a single step of affinity purification resulted in FLAG-tagged proteins of the expected sizes (the apparent size of mCHL(s2) was approximately 38 kD). During the purification, it was noticed that the expression levels as well as the integrity of mCHL(s2)-FLAG in serum-free conditioned media depended entirely on the type of medium used. For instance, DMEM with or without insulin and transferrin yielded only a very low level of the protein, which was mostly degraded (Fig. 3C) . Other media, such as s-MEM and IMDM, also gave similar results (data not shown). The degradation product that cross-reacted with the anti-NH 2 -terminal peptide antibody was approximately 28 kDa in size (Fig. 3C) , and those that cross-reacted with the anti-FLAG antibody were 14 to 16 kDa (Fig. 3B) . Based on the sizes of these degradation products, the predicted degradation sites were mapped between CR2 and CR3. In contrast, 293 SFM II protected the mCHL(s2)-FLAG protein from degradation and gave reasonable expression levels. Nevertheless, the CHL protein seemed to be unstable and susceptible to protease attack.
FIG. 5. Inhibitory effects of mCHL(s2) and mouse chordin proteins on the BMP4-dependent differentiation of ES cells in vitro. (A) Effects on the generation of the CD34
ϩ CD31 hi lymphohematopoietic progenitor cell fraction (R1), the CD34 ϩ CD31 lo erythromyeloid progenitor cell fraction (R2), and the CD45 ϩ myelomonocytic cell fraction (R3). Seven-day-old embryoid bodies (EBs) generated without a factor (No factor), with BMP4 (BMP4), with BMP4ϩ0.4 g/ml mCHL(s2)-FLAG (BMP4ϩCHL), and with BMP4ϩ0.5 g/ml mCHD-FLAG (BMP4ϩCHD) were harvested and analyzed for CD34, CD31, and CD45 protein expression. Numbers indicate percentages of total EB cells. (B) Dose-dependent inhibition of the BMP4-dependent generation of the CD34 ϩ CD31 ϩ progenitor cell fraction. ES cells were differentiated in the presence of BMP4 and various concentrations of mCHL(s2)-FLAG or mCHD-FLAG protein. The CD34 ϩ CD31 ϩ EB cell populations (R1ϩR2) were individually normalized in each experiment so that 100% corresponds to the CD34 ϩ CD31 ϩ EB cell fraction obtained without mCHL-FLAG and mCHD-FLAG. Values obtained from two to three independent experiments were averaged and plotted according to the concentration of mCHL(s2)-FLAG (ᮀ) and mCHD-FLAG protein (᭛) added. The vertical bars are the standard deviation.
Direct Interaction of mCHL(s2) with BMPs and Inhibition of BMP Binding to the Receptor by mCHL(s2)
The direct interaction of the Xenopus chordin protein with human BMP4 has been demonstrated (Piccolo et al., 1996) . Similar experiments were performed using the mouse chordin and mouse CHL proteins. As shown in Figs. 4A and 4B, both the mCHD-FLAG and mCHL(s2)-FLAG proteins co-immunoprecipitated with BMP4, BMP5, and BMP6. However, under the low concentration condition (Fig. 4A) , BMP5 showed no sign of interaction with mCHL(s2)-FLAG and a very weak interaction with mCHD-FLAG. On the other hand, BMP6 gave significantly weaker signals for both proteins compared with the high concentration condition. These observations suggest that both chordin and CHL might have weaker affinities with BMP5 and BMP6 than with BMP4. Activin A, another TGF␤ superfamily member, showed no sign of interaction with chordin and CHL under either set of conditions. BMP2 and BMP4 form a separate subfamily from BMP5, BMP6, and BMP7 (Celeste et al., 1990) . Thus, both the chordin and CHL proteins may be pan-BMP binding proteins. Interestingly, mCHL(s2)-FLAG, but not mCHD-FLAG, interacted with TGF␤1 (data not shown) and TGF␤2 (Fig. 4B) under the high concentration condition.
Chordin prevents BMP action by inhibiting the interactions of BMPs with their receptors. Therefore, we determined whether CHL functioned in a similar fashion. The extracellular domain of the BMP receptor 1B fused to the Fc portion of human IgG (BMPR1BFc) was mixed with BMP4 and was precipitated with protein A beads. As shown in Fig.  4C , without the mCHL(s2)-FLAG protein, BMP4 was coprecipitated with BMPR1BFc but not with Fc, indicating that BMP4 bound specifically to the BMPR1B extracellular domain. With increasing amounts of mCHL(s2)-FLAG added, however, the BMP4 signal became weaker. At concentrations of 0.5 g/ml or higher, the reduction was especially evident. This result suggests that, similar to chordin, CHL may also prevent BMP4 from binding to the receptor.
MCHL(s2) Inhibits BMP4 Action in Vitro
Complex formation with chordin is known to inhibit BMP4 function. Judging from the similar axis duplication activity to chordin, CHL would also inhibit BMP4 action directly. We have demonstrated previously that the generation of CD34 ϩ CD31 hi lymphohematopoietic progenitor cells, CD34 ϩ CD31 lo erythromyeloid progenitor cells, and CD45 ϩ myelomonocytic cells is dependent on the presence of 0.15 to 2 ng/ml of BMP4 during the differentiation of mouse ES cells (Nakayama et al., 2000) . A BMP4 concentration of 0.6 ng/ml resulted in an approximately halfmaximal level (data not shown). When affinity-purified mCHL(s2)-FLAG and mCHD-FLAG proteins were each added, at 10 to 500 ng/ml per assay, the CD34 ϩ CD31 hi , CD34 ϩ CD31 lo , and CD45 ϩ cell populations were significantly reduced (Fig. 5A) , and this inhibition was dosedependent (Fig. 5B) . These results suggest that the FLAGtagged CHL and chordin proteins were each able to inhibit the action of BMP4 in vitro.
Localization of CHL mRNA Expression
A Northern blot analysis indicated that CHL and chordin were differentially expressed over time during mouse embryogenesis (Fig. 6A) . The E7 mouse embryo as a whole expressed chordin mRNA but not CHL mRNA, whereas the pattern was reversed in embryos later than E11. In the adult mouse (Fig. 6B) , distinct patterns of expression were maintained. CHL transcripts 4 kb in length were present in brain, lung, kidney, and testis. However, liver expression was consistently very low. On the contrary, the chordin mRNA was detected mainly in the liver and brain. In humans, the chordin mRNA was detected predominantly in the liver (data not shown).
It is worth noting that no transcript significantly longer than 4 kb was observed on the Northern blots. Furthermore, the specific probe for the mCHL(s) mRNA (intron 9 probe) detected only transcripts with a similar size (approximately 4 kb) in mouse embryos and adult tissues. The intron 9 of the human CHL gene is approximately 6.9 kb in length. Assuming that the intron 9 of the mouse CHL gene has a similar size, these observations support the idea that the mCHL(s) mRNA might be generated by premature termination (Fig. 1C) .
CHL mRNA Expression during Skeletogenesis
An in situ hybridization analysis revealed CHL expression beginning around embryonic day 9.5 and persisting in a wide range of adult stromal and connective tissue cell types of mesenchymal origin. No CHL signal was detected in the sections examined at E8.5. At E9.5, the signal was just barely detectable over the somites but not the limb bud (data not shown). At E10.5, strong signals were seen over the dermatome portion of the somites and diffusely over the limb bud mesenchyme (Figs. 7A-7D ). In the E11.5 limb (Figs. 7G and 7H ) and elsewhere throughout the developing skeleton (data not shown), the CHL mRNA was present over areas of mesenchymal cells concurrent with the formation of precartilaginous mesenchymal condensations. At E12.5, this included the cephalic mesenchyme in areas where the basioccipital and exoccipital bones form, over mesenchymal cells in the mandible, and adjacent to the dorsal root ganglia in areas where vertebrae would form (data not shown). At E13.5, strong CHL signals were detectable over the hypertrophic chondrocytes in limb bones (Figs. 7I and 7J) , clavicle, and sternum, as well as in the perichondrial mesenchymal cells adjacent to the developing joints. Strong CHL expression continued in the hypertrophic chondrocytes within the developing bones (E15.5, Figs. 7E, 7F, 7K, and 7L) and began to decline in the perichondrial mesenchymal cells, a pattern that contrasts with that of chordin (Fig. 7M) , which was strikingly absent in the cartilage elements. By E18.5 and through to the adult, the skeletal expression of CHL was present at diminished levels and was restricted to the hypertrophic chondrocytes at the epiphyseal growth plate, scattered cells in the bone marrow, which appeared to be a population of bone marrow stromal cells (Figs. 7N,  7O , 8A, and 8B), and at barely detectable levels in the articular chondrocytes at the joint surfaces.
Nonskeletal Expression of CHL
CHL was also expressed in a range of nonskeletal mesenchymal cell types. Expressions in subdermal fusiform stromal cells, connective tissue cells of the epimysium and perimysium surrounding bundles of skeletal muscle, a layer of fibroblast/connective tissue cells dividing the submucosa and muscularis of the gastrointestinal tract ( Figs 8C and  8D) , and perivascular cells were all detectable embryonically and persisted into adulthood. A strong and striking pattern of adult CHL expression was present in the outer medulla and medullary rays of the kidney (Fig. 8E) . The CHL-positive cells formed segments of proximal and distal tubules, derived from the nephrogenic mesenchyme (Fig.  8F ). Additional sites of adult CHL expression included trabecular connective tissue cells in the lymph nodes, perivascular cells in the lung, myofibroblasts in the uterus, and stromal cells in white adipose tissue (data not shown).
In addition to these mesenchymal cell types, the signal was detected at E10.5 in the differentiating fields of the ventral telencephalon and the dorsal rhombencephalon, which are destined to become the olfactory bulb and the cerebellum, respectively. Other parts of the developing nervous system lacked CHL expression. The CHL expression in these regions persisted through embryonic development, and adult cerebellar Purkinje cells (Figs. 8G and 8H) , olfactory bulb neurons, and cerebral cortical neurons (and glia-like cells) continued to express CHL.
Thus, the CHL gene was expressed preferentially in cell types originating from the embryonic mesenchyme. The only nonmesenchymal cell lineage expressing the CHL mRNA was the neuron.
FIG. 6.
Differential expression of the CHL gene and the chordin gene. Northern blot analyses were performed using Clontech blots. The blots were first probed with a DNA containing the mCHL(s2) ORF (CHL) and then were reprobed with the mouse chordin cDNA (CHD) and finally with the human ␤-actin fragment (␤-actin). Three different batches of blots were used. All gave essentially the same results. A separate batch of RNA blot was probed with the intron 9 probe to detect the mCHL(s)-specific transcript (CHL(s)). The pattern of expression of the ␤-actin mRNA (not shown) was indistinguishable from that shown here. (A) Mouse embryo blot made with E7 (7), E11 (11), E15 (15), and E17 (17) In situ hybridization with a chordin probe in an E15.5 section adjacent to K demonstrates a conspicuous lack of chordin expression in cartilage elements. (N, O) At E18.5, CHL expression in bone is restricted to hypertrophic chondrocytes at the epiphyseal growth plates. Abbreviations used: lb, limb bud; h, heart; hu, humerus; ra, radius; eso, esophagus; sp, spinal cord; na, neural arch; gut, intestine; d, digit; li, liver; lu, lung. Scale bars are indicated on the brightfield panels. 
DISCUSSION
We have demonstrated that a novel X-linked chordin-like gene, CHL, encodes a protein that directly interacts with BMPs and inhibits their actions in vitro as well as in vivo. The expression analysis suggests a possible role of CHL during skeletogenesis as well as in several other organogenic processes. This is the first demonstration that a chordin-type BMP inhibitor forms a gene family in mammals.
Structure and Function of CHL
Based on the Gap analysis (Genetics Computer Group), the overall amino acid sequence similarity between the mouse chordin and mCHL(s2) was 28%, and the nucleic acid homology of the ORF was 37%. Only the CR units showed statistically significant homology. Therefore, the sequence homology was not sufficient to imply functional similarities between chordin and CHL. However, when injected into early Xenopus embryos, the CHL RNA showed a clear axis duplication activity similar to that of mouse chordin RNA (Fig. 2) . In fact, recombinant mCHL(s2) protein and mouse chordin protein were able to interact directly with the three BMPs tested (Fig. 4) . Both proteins also inhibited BMP function in vitro when added to the serum-free differentiation culture of ES cells, which leads to the generation of lymphohematopoietic progenitor cells in a BMP4-dependent manner (Fig. 5 and Nakayama et al., 2000) . Furthermore, the inhibition of BMP action by the mCHL(s2) protein seemed to be achieved by preventing BMP4 from interacting with the BMP receptor (Fig. 4C) . These results suggest that CHL is not only structurally related to but also functionally similar to chordin.
One difference in the activities of CHL and chordin was the target specificity. MCHL(s2) showed weak but sufficient binding capability to be coprecipitated with TGF␤1 (data not shown) and TGF␤2 (Fig. 4B) when the high concentration conditions were used. In contrast, mouse chordin did not show any sign of interaction with them, consistent with the properties of Xenopus chordin (Piccolo et al., 1996) . However, we still have not succeeded in determining whether the interaction with CHL inhibits TGF␤ function.
CHL was present in multiple forms in both mouse and human (Fig. 1) . As in the case of chordin, these variations could change some of the CHL activities (Yu et al., 2000) . However, given that the two long forms, l1 and l2, and the two short forms, s1 and s2, induced a secondary axis in the Xenopus embryo (Table 1) , all forms are likely to share the BMP-antagonizing activity. Interestingly, all of the variations are located outside the CRs: E 95/96 directly follows CR1, the GKKAK is immediately after CR3, and the short form contains an altered COOH-terminal sequence after the GKKAK (Fig. 1B) . Since the CRs are the binding sites for BMPs (Larrain et al., 2000) , these variations may not affect the CHL's binding specificity to BMPs. On the other hand, they may affect the stability and/or integrity of the protein.
In this regard, it is worth noting that the axis duplication rates obtained with the long forms of hCHL fluctuated significantly, even when 1 ng of RNA was injected per blastomere, while the short forms of hCHL gave more consistent and higher values, suggesting that the short forms might be more stable and/or active than the long forms of CHL.
The mCHL(s2) protein was unstable and readily degraded in conditioned media (Fig. 3C) . This was also the case for the hCHL(l1) protein (data not shown). Therefore, CHL protein instability does not seem to be specific for either the mouse protein or the short form. It is known that BMP1/ Tolloid inactivates chordin (Piccolo et al., 1997; Scott et al., 1999) . Interestingly, CHL contained potential BMP1 target sites between CR2 and CR3, the area consistent with our estimated degradation sites (Fig. 1) . Therefore, CHL could be under the BMP1-dependent control mechanism. There were also several potential cleavage sites (K/R-(X)n-K/R, n ϭ 0, 2, 4, or 6) for proprotein convertase between CR2 and CR3 (reviewed in Seidah and Chretien, 1999) . Therefore, what appeared to be degradation products could be mature forms of CHL. These degraded/processed products of CHL may show very weak inhibitory activity (Larrain et al., 2000) and/or possess altered target specificity (Yu et al., 2000) , as in the case of chordin. Supporting the former, the mCHL(s2) preparation, made through transient transfection of 293T cells, which was mostly composed of degraded/ processed products (Fig. 3C) , was not active in suppressing BMP4 activity during ES cell differentiation (data not shown). Thus, if the degraded/processed forms are the functional forms in vivo, then the biological role of CHL could be agonistic instead of antagonistic to BMP action.
Further biochemical characterizations of CHL as well as the CHL variants and genetic analysis of the CHL gene would provide definitive answers to these questions.
Biological Implications of CHL
The CHL transcript was first detected in the somites of the E9.5 mouse embryo, and at E10.5, strong signals were observed in the dermatome and limb bud mesenchymes (Figs. 7A-7D) . Consistently, the developing skeletal structure, including limb bones, clavicle, calvaria, vertebra, and rib (ex. at E15.5, Figs. 7E and 7F), was one of the major CHL expression sites during embryogenesis. During the limb bone formation, the CHL expression was first detected in the precartilaginous mesenchymal condensation of the limb bud (Figs. 7G and 7H ) and later was restricted to the hypertrophic chondrocytes in the epiphyseal growth regions, and its expression levels progressively diminished as the embryo developed (Figs. 7I-7O and 8A ). On the contrary, the chordin-expressing sites in the forelimb did not overlap with the CHL-expressing areas (they were like a mirror image), suggesting that chordin and CHL would have different and/or non-overlapping biological roles during limb formation (Figs. 7K-7M ). This observation supports the previous finding that in the E15.5 hindlimb, the chordin transcript is detected throughout the limb mesenchyme, with particularly high levels of expression overlying the perichondrium of the ossifying cartilage of the femur as well as that of the cartilage primordia of the tarsals, metatarsals, and phalanges (Scott et al., 1999 (Scott et al., , 2000 . Similarly, Gremlin, another BMP binding inhibitor family, is expressed in the nonchondrogenic region of the limb bud and later in the interdigital mesenchyme and the differentiating perichondrium (Merino et al., 1999) . However, the expression sites of the CHL mRNA in the developing limb overlapped somewhat with those of noggin mRNA, including the mesenchymal condensations in the limb bud and the chondrocytes of the developing limb bone (Brunet et al., 1998; Capdevila and Johnson, 1998; Merino et al., 1998; Nifuji and Noda, 1999; Pathi et al., 1999) . Nevertheless, since BMPs are expressed in the limb cartilage, the sternum, and the rib during mouse embryogenesis (Solloway et al., 1998; and reviewed in Wozney et al., 1993) and are implicated in many stages of bone formation (reviewed in Karsenty, 1998) , these results support the hypothesis that CHL may participate in regulating BMP action during skeletogenesis, and the biological role of CHL may be shared in part by noggin.
On the other hand, the expression of CHL mRNA in nonskeletal mesenchymal cells in the embryo, such as subdermal mesenchymes and gut mesenchymes (Figs. 7E and 7F), seemed to continue into many adult connective tissue cell types. For example, in the stomach, the intestine, and the colon, the expression was localized specifically on a layer of fibroblasts/connective tissue cells that divided the submucosa and muscularis (Figs. 8C and 8D ). In contrast, the chordin signal was detected weakly over the connective tissue cells in the muscularis of the gastrointestinal tract and was never restricted to a single layer (data not shown). During the gastrointestinal development of the chicken, BMP4 is induced in the non-smooth muscle mesenchyme around the endodermal epithelium, which later differentiates into the submucosa, and inhibits the differentiation of smooth muscle and enteric neurons in the muscularis (Smith et al., 2000; Sukegawa et al., 2000) . In this respect, the layer of CHL-expressing cells may serve as a wall that prevents the migration of active BMPs into the muscularis. Furthermore, the strong CHL signal in the tubules of the kidney outer medulla (Figs. 8E and 8F) suggests that CHL may also be involved in mesenchymal cell differentiation during nephrogenesis, especially because BMP is required for the nephrogenic mesenchyme to grow and survive, but is inhibitory for tubulogenesis (Dudley et al., 1999) . In contrast, the chordin signal was observed only in a layer of connective tissue/fibroblast-like cells beneath the urothelium lining, the portion of the renal pelvis that connects to the ureter (data not shown). Thus, CHL and chordin are also differentially expressed in the kidney.
CHL mRNA expression in mesenchymal cell lineages is consistent with our isolation of the cDNA from the preadipocytic stromal cell line OP9. In fact, in both the vertebrae (data not shown) and the adult femur (Fig. 8B) , the in situ hybridization signal was detected over the nonhematopoietic cell types in the marrow space. The chordin signal in the bone marrow was too weak to detect (data not shown). Whether CHL and BMPs have any role in hematopoiesis remains to be determined. In this respect, it is worth mentioning that the CHL mRNA expression in bone marrow stromal cell lines has some correlation with their ability to support long-term in vitro hematopoiesis (data not shown).
The expression of CHL in restricted areas of the developing brain suggests a possible role of CHL in the regulation of BMP activity during the generation of specific neurons: olfactory bulb neurons and Purkinje cells. Supporting this hypothesis, BMPs are expressed on the Purkinje cell layer (Nakashima et al., 1999; Zhao et al., 1999) , and the involvement of BMPs in cerebellar granule neuron genesis has been demonstrated recently (Alder et al., 1999) . Interestingly, there were also differences between the expression domains of chordin and those of CHL in the adult brain. For instance, a strong chordin signal was detected over the hippocampus (including the dentate gyrus), where the CHL signal was absent (N. Nakayama, unpublished results; Scott et al., 2000) . Furthermore, in the cerebellum, the chordin transcript was detected over granule cells, but not on Purkinje cells (N. Nakayama, unpublished results; Scott et al., 2000) .
In conclusion, a large body of evidence has suggested that the function of BMP is regulated by a variety of binding proteins in the extracellular space. In this respect, the identification of CHL provides additional support for the idea that this regulatory mechanism is widely employed for BMPs and that individual BMP binding proteins are responsible for eliciting the distinct biological roles of the BMPs. Some questions remain: does CHL play an indispensable role at any of the expression sites and is the spatiotemporal control of CHL gene expression critical? However, the results that CHL inhibited BMP action, that the main and initial expression sites during embryogenesis were the developing skeleton, and that it was differentially expressed from chordin in many areas have prompted us to speculate that there may be a biological process in which CHL plays an essential role and that it would include skeletogenesis. Thus, the present demonstration may also provide further insights into how BMP actions are regulated spatially and temporarily during organogenesis.
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